Movement Alert｜ImmunityBio, Inc. Intraday Decline 6%, Q3 loss expansion and revenue miss continued to pressure shares

Market Focus11-12 23:04

On November 12, ImmunityBio, Inc. recorded an Intraday Decline of 6% in Regular Trading, trading at $6.3102 per share, with turnover of $17.3471 million.

The clearest catalyst remained continued investor pressure after the company reported weaker-than-expected third-quarter results, with the latest market update indicating that the earnings miss and widening loss were still weighing on sentiment.

For the quarter ended September 30, ImmunityBio, Inc. reported revenue of $48.841 million, up from $32.1 million a year earlier but below the $59.25 million consensus. Net loss widened to $0.18 per diluted share from $0.07 a year earlier, also worse than expectations. Although the company separately disclosed Anktiva clinical progress in non-muscle invasive bladder cancer and regulatory advancement in Israel and Europe, those developments did not offset concerns around financial performance and commercialization execution.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment